Drugmaker AbbVie is accused of maintaining a series of agreements with generic drugmakers to delay generic competition against branded blood-pressure drug Bystolic until September 2021. The complaint, filed yesterday in California federal court, is the first pay-for-delay suit over Bystolic.The complaint alleges that the agreements were first struck by Forest Laboratories —